Search

Your search keyword '"Migraine -- Prevention"' showing total 355 results
Start Over Descriptor "Migraine -- Prevention"
355 results on '"Migraine -- Prevention"'

1. Pharmacologic prevention of migraine

Author

Tzankova, Velina, Becker, Werner J., and Chan, Tommy L.H.

Subjects
Botulinum toxin -- Dosage and administration, Migraine -- Prevention, Monoclonal antibodies -- Dosage and administration, Health
Abstract

In this second in a series of 2 reviews focusing on the management of migraine, we discuss pharmacologic treatments that health care practitioners may prescribe to help reduce the frequency, [...]

Published
2023
Full Text
View/download PDF

3. Patients in England to be offered daily pill that can halve migraine frequency; Nice approves first oral treatment with Atogepant that can prevent chronic and episodic migraines

Subjects
AbbVie Ltd. (Maidenhead, England), Migraine -- Prevention, Pharmaceutical industry, News, opinion and commentary
Abstract

Byline: Andrew Gregory Health editor Thousands of people in England who suffer from migraines are to be offered a daily pill on the NHS that can reduce the frequency of [...]

Published
2024

5. Migraine Prevention Med Might Stop 'Rebound' Headaches, Too

Author

Miller, Carole Tanzer

Subjects
Headache -- Risk factors, Migraine -- Prevention, Analgesics -- Dosage and administration -- Complications and side effects, Health
Abstract

Byline: Carole Tanzer Miller HealthDay Reporter THURSDAY, June 27, 2024 (HealthDay News) -- It's a nasty cycle: Chronic migraine sufferers who use too much pain medication sometimes get smacked with [...]

Published
2024

6. New pill to prevent chronic migraines to be available on NHS; People who suffer from debilitating headaches at least four days a month will be eligible for atogepant

Subjects
AbbVie Ltd. (Maidenhead, England), Migraine -- Prevention, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

Byline: Laura Donnelly, Health Editor A new pill to prevent chronic and episodic migraines will be rolled out on the NHS, with some 170,000 sufferers eligible. A migraine charity has [...]

Published
2024

7. Researcher at Beth Israel Deaconess Medical Center Discusses Research in Migraine (Novel insight into atogepant mechanisms of action in migraine prevention)

Subjects
Medical centers -- Reports, Migraine -- Prevention, Biological sciences, Health, Beth Israel Deaconess Medical Center -- Reports
Abstract

2024 MAR 19 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- New study results on migraine have been published. According to news originating from Boston, [...]

Published
2024

9. Researchers Submit Patent Application, 'Methods of Treating or Preventing Migraine or Repetitive Occurrence of Common Migraine Headaches in a Subject Having Underlying Condition(s)', for Approval (USPTO 20240000906)

Subjects
Mental health -- Methods, Mentally ill -- Methods, Migraine -- Prevention, Mental illness -- Prevention, Health, Psychology and mental health
Abstract

2024 JAN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- From Washington, D.C., NewsRx journalists report that a patent application by the inventor [...]

Published
2024

10. Findings on Headache Reported by Investigators at University of Aquila (European Headache Federation Guideline On the Use of Monoclonal Antibodies Targeting the Calcitonin Gene Related Peptide Pathway for Migraine Prevention-2022 Update)

Subjects
Genes, Nervous system diseases -- Prevention, Migraine -- Prevention, Monoclonal antibodies, Calcitonin, Peptides, Evidence-based medicine, Health
Abstract

2024 JAN 5 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Nervous System Diseases and Conditions - Headache. According [...]

Published
2024

13. Study Findings on Migraine Described by a Researcher at University of Illinois College of Medicine Peoria (Placebo response with subcutaneous injections in calcitonin gene-related peptide receptor monoclonal antibody migraine preventative ...)

Subjects
Migraine -- Prevention, Monoclonal antibodies -- Reports -- Analysis, Peptides -- Analysis -- Reports, Physical fitness -- Analysis -- Reports, Health
Abstract

2022 SEP 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on migraine is the subject of a new report. According [...]

Published
2022

14. Researchers from Menoufia University Report Details of New Studies and Findings in the Area of Migraine (The Impact of Vitamin D-3 Supplementation To Topiramate Therapy On Pediatric Migraine Prophylaxis)

Subjects
Alfacalcidol -- Testing, Migraine -- Prevention, Calcifediol -- Testing, Vitamin D -- Testing, Pediatric research, Topiramate -- Testing, Health
Abstract

2022 JUL 23 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Primary Headache Diseases and Conditions - Migraine have been [...]

Published
2022

15. Lundbeck presents clinical advances in migraine prevention with positive trial results at international headache congress

Subjects
H. Lundbeck A/S -- Product development -- Political activity, Migraine -- Prevention, Clinical trials -- Political aspects, Pharmaceutical industry -- Product development -- Political activity, Business, Chemicals, plastics and rubber industries
Abstract

H. Lundbeck A/S announces new clinical data supporting the efficacy and tolerability of Lu AG09222 for the preventive treatment of migraine at the International Headache Congress (IHC) 2023 in Seoul, Korea. The presentations also include additional data from a proof-of-mechanism study showing that Lu AG09222 can halt PACAP38-triggered vasodilation and headaches. Lu AG09222 is an investigational mAb intended to block signals by PACAP. This neuropeptide is believed to contribute to migraine. The data represents the first positive headline results with this mechanism. Lu AG09222 may offer a potential new treatment option. It aims at a migraine pathway that is distinct from the pathway targeted by the recently introduced anti-calcitonin gene-related peptide (anti-CGRP) treatment approach. Based on these positive outcomes, Lu AG09222 will progress into further development. Ashina, M et al. Efficacy and safety of Lu AG09222 for migraine prevention in patients with 2-4 previous preventive treatment failures: HOPE, an interventional, randomized, double-blind, parallel-group, placebo-controlled Phase 2 trial. HOPE was an interventional, randomized, double-blind, parallel-group, placebo-controlled Phase 2 trial (NCT05133323), conducted in Georgia, Poland, Czechia, Denmark, and US. A total of 237 participants were randomized in this trial (Lu AG09222 high dose, 97; Lu AG09222 low dose, 46; and placebo, 94). Participants were 87.8% female with a mean age of 42.5 and 16.7 monthly migraine days (MMDs) at baseline. This trial met the primary endpoint; the difference from placebo in mean change in MMDs from baseline over weeks 1-4 was significant with the Lu AG09222 high dose [-2.0 (90%CI -3.5; -0.6); one-sided p=0.01]. The change from baseline in mean MMDs was -6.2 (standard error [SE] 0.66) with Lu AG09222 high dose and -4.2 (SE 0.67) with placebo. Lu AG09222 was generally well tolerated. Rasmussen, N et al. PACAP-targeted antibody Lu AG09222 inhibits vasodilation in healthy volunteers. This was an interventional, randomized, double-blind, parallel-group, placebo-controlled, phase 1 trial (NCT04976309). Lu AG09222 inhibited PACAP38-induced cephalic vasodilation and increases in heart rate and reduced concomitant headache. Together, these data support Lu AG09222 as a potential preventive treatment of migraine. They further confirm a role of PACAP in migraine pathophysiology, in addition to the established role of CGRP that is targeted by the current advanced migraine therapies [anti-CGRPs]. With its novel mechanism of action, Lu AG09222 has the potential to help patients with migraine and potentially other pain related indications. Lundbeck is grateful to all the trial participants, and the investigators who contributed greatly to this research. Original source: Lundbeck, website: http://www.lundbeck.com/, Copyright H Lundbeck A/S 2023., research and development; antimigraine agents; monoclonal antibodies; neuropeptide; therapeutic antibodies; H. [...]

Published
2023

18. Emgality's effectiveness in preventing episodic migraines is reaffirmed in a groundbreaking head-to-head clinical trial

Subjects
Eli Lilly and Co. -- Product development, Migraine -- Prevention, Clinical trials, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, Nurtec (Medication) -- Product development, Emgality (Medication) -- Product development
Abstract

INDIANAPOLIS: Eli Lilly and Company has announced the results of the Challenge-MIG clinical trial comparing Emgality and Nurtec ODT, the first of its kind. Emgality did not meet the primary [...]

Published
2023

19. First-of-its-kind head-to-head clinical trial reaffirms the efficacy of Emgality in episodic migraine prevention

Subjects
Eli Lilly and Co. -- Product development, Migraine -- Prevention, Clinical trials, Pharmaceutical industry -- Product development, Business, Chemicals, plastics and rubber industries, Nurtec (Medication) -- Product development, Emgality (Medication) -- Product development
Abstract

Eli Lilly and Company announced results of the CHALLENGE-MIG clinical trial of Emgality (galcanezumab-gnlm) and Nurtec ODT (rimegepant orally disintegrating tablet), the first and only trial of its kind comparing two calcitonin gene-related peptide (CGRP) antagonist therapies. Emgality did not meet the study's primary endpoint, defined as statistical superiority to Nurtec ODT on the percentage of participants achieving a 50% or greater reduction in monthly migraine headache days. Response rates were similar. However, it demonstrated clinically meaningful efficacy and safety in this 3-month study consistent with Emgality's previous 6-month studies. And, Emgality performed numerically better on key secondary endpoints of the 3-month trial. Original source: Eli Lilly, website: http://www.lilly.com/, Copyright Eli Lilly and Company 2023., research and development; antimigraine agents; Emgality; galcanezumab-gnlm; Nurtec ODT; rimegepant; Eli Lilly and [...]

Published
2023

20. Using Nerivio(r) for Migraine Prevention Results in Significant Clinical and Cost-Saving Benefits for Patients, Insurers, and Employers, According to a New Health Economics Study

Subjects
Medicine, Preventive -- Economic aspects, Employers -- Economic aspects, Migraine -- Prevention, Preventive health services -- Economic aspects, General interest, News, opinion and commentary
Abstract

NETANYA: Theranica has issued the following news release: Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, announced the results of a recent [...]

Published
2023

21. First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

Subjects
Eli Lilly and Co. -- Product development, Medical research, Medicine, Experimental, Migraine -- Prevention, Clinical trials, Pharmaceutical industry -- Product development, Health, Nurtec (Medication) -- Product development, Emgality (Medication) -- Product development
Abstract

2023 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Eli Lilly and Company (NYSE: LLY) announced results of the CHALLENGE-MIG clinical trial [...]

Published
2023

23. AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China

Subjects
Eli Lilly and Co. -- International economic relations, Migraine -- Prevention, Pharmaceutical industry -- International economic relations, Business, News, opinion and commentary
Abstract

Affamed to obtain sole commercialization rights upon regulatory approval in Mainland China to Galcanezumab, a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP). Target to address unmet medical [...]

Published
2023

24. Vitamin [D.sub.3] supplementation may aid in preventing migraine

Subjects
Medicine, Preventive -- Evaluation, Alfacalcidol -- Health aspects, Migraine -- Prevention, Calcifediol -- Health aspects, Vitamin D -- Health aspects, Preventive health services -- Evaluation, Teenagers -- Health aspects, Youth -- Health aspects, Health, Health care industry
Abstract

In children who are subject to migraine attacks, vitamin D supplementation may be an effective and safe adjunctive prophylactic therapy to topiramate, results of a study in Saudi Arabia showed. [...]

Published
2023

25. 'Peptide Immunogens Targeting Pituitary Adenylate Cyclase-Activating Peptide (Pacap) And Formulations Thereof For Prevention And Treatment Of Migraine' in Patent Application Approval Process (USPTO 20230146694)

Subjects
Migraine -- Prevention, Amino acids -- Intellectual property, B cells, Vaccines -- Intellectual property, Peptides, Health
Abstract

2023 MAY 31 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- A patent application by the inventors Ding, Shuang (Hauppauge, NY, US); Lin, Feng (Hauppauge, NY, [...]

Published
2023

26. 7 tips to prevent stress-triggered migraines for Stress Awareness Month; Do you frequently suffer from migraines? Stress might be a key reason for them. This Stress Awareness Month, here are seven expert tips to prevent stress-triggered migraines

Subjects
Migraine -- Prevention, Stress management, General interest, News, opinion and commentary
Abstract

Byline: By, Malvika Padin Fast-paced lifestyles and increased screen time in this digital age mean that more and more people are suffering with migraines. Migraines are a common condition in [...]

Published
2022

27. Petasites for Migraine Prevention Deemed Safe and Effective

Subjects
Migraine -- Prevention, Medicine, Botanic -- Reports, Medicine, Herbal -- Reports, General interest, News, opinion and commentary
Abstract

TAMPA: Linpharma has issued the following news release: A new study published in Frontiers in Neurology, one of the most-cited journals in its field, details important data on mode of [...]

Published
2022

28. 15-Site Trial to Compare Telehealth Cognitive Behavior Therapy Alone and with Medication to Prevent Migraine in Youth

Subjects
Cognitive therapy, Migraine -- Prevention, Behavioral health care, Clinical trials, Evidence-based medicine, Business, News, opinion and commentary, Children's Hospital Medical Center
Abstract

CINCINNATI, July 26, 2022 /PRNewswire/ -- Researchers at Cincinnati Children's have been approved for a $12.9 million funding award by the Patient-Centered Outcomes Research Institute (PCORI) to lead a multi-center [...]

Published
2022

30. Findings from Institute of Experimental Neurology in the Area of Headache Described (Candesartan in migraine prevention: results from a retrospective real-world study)

Subjects
Candesartan, Physical fitness, Angiotensin II, Nervous system diseases -- Prevention, Migraine -- Prevention, Health
Abstract

2020 JUL 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Nervous System Diseases and Conditions - Headache. [...]

Published
2020

31. Recent Studies from Hubei University of Chinese Medicine Add New Data to Migraine Disorders (Impact of the Botulinum-a Toxin On Prevention of Adult Migraine Disorders)

Subjects
Physical fitness -- Analysis, Medical research -- Analysis, Asian medicine -- Analysis, Migraine -- Prevention, Obesity, Editors, Headache, Diseases, Health
Abstract

2020 MAY 2 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Primary Headache Diseases and Conditions - Migraine [...]

Published
2020

32. Atogepant Prevents Migraine in Adults

Subjects
Medicine, Preventive -- Reports, Migraine -- Prevention, Preventive health services -- Reports, Adults -- Reports, News, opinion and commentary, Sports and fitness
Abstract

WEDNESDAY, June 15, 2022 (HealthDay News) -- Atogepant appears to be effective and well tolerated for the preventive treatment of migraine, according to a study published online June 8 in [...]

Published
2022

33. Lundbeck to Present Data on VYEPTI(r) (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention

Subjects
Medicine, Preventive, Migraine -- Prevention, Preventive health services, General interest, News, opinion and commentary
Abstract

DEERFIELD, Ill.: Lundbeck has issued the following news release: Lundbeck today announced data on VYEPTI(r) (eptinezumab-jjmr) will be presented at the 64th Annual Scientific Meeting of the American Headache Society [...]

Published
2022

34. Lundbeck to Present Data on VYEPTI[R] (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention

Subjects
H. Lundbeck A/S, Migraine -- Prevention, Pharmaceutical industry, Business, Business, international
Abstract

* Nine poster presentations reinforce the scientific evidence for eptinezumab as a preventive migraine treatment in adults * Two separate post-hoc analyses from the pivotal PROMISE-1 and PROMISE-2 studies showed [...]

Published
2022

37. Migraine Care: Prevention, Treatment, and Medication Management: Various pharmacologic and nonpharmacologic therapies are available

Author

Berger, Karen

Subjects
Pharmacists, Migraine -- Prevention, Monoclonal antibodies, Business, Pharmaceuticals and cosmetics industries
Abstract

Twelve percent of the US population experiences migraine, according to the Migraine Research Foundation. Migraine is the third most prevalent illness globally, and it affects 1 in 4 US households. [...]

Published
2021

38. Robust Uptake of AbbVie's Qulipta Turns Up the Pressure for Amgen, Eli Lilly, and Teva in the Prevention Segment of the Migraine Market, Spherix Reports

Subjects
Eli Lilly and Co., Medicine, Preventive, Migraine -- Prevention, Preventive health services, Pharmaceutical industry, Business, News, opinion and commentary, Ajovy (Medication), Nurtec (Medication), Emgality (Medication)
Abstract

Needle aversion and oral therapy preference is costing new prescription opportunities for Amgen's Aimovig, Eli Lilly's Emgality, and Teva's Ajovy EXTON, Pa., Feb. 8, 2022 /PRNewswire/ -- The September 2021 [...]

Published
2022

39. United States : Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs

Subjects
United States. Food and Drug Administration, Migraine -- Prevention, Drug approval, Clinical trials, Business, international
Abstract

Tonix Pharmaceuticals Holding Corp. (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) Application to [...]

Published
2021

40. Patent Issued for Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light a version in subjects in need thereof, especially migraine sufferers (USPTO 11325967)

Subjects
Biological products -- Intellectual property, Viral antibodies, Migraine -- Prevention, Antibodies, Health
Abstract

2022 MAY 30 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- A patent by the inventors Garcia-Martinez, Leon F. (Woodinville, WA, US), Kaiser, Eric A. (Iowa [...]

Published
2022

41. Studies from Shahid Sadoughi University of Medical Sciences and Health Services in the Area of Headache Reported (The Preventive Effect of the Combination of Atorvastatin and Nortriptyline In Migraine-type Headache: a Randomized, Triple-blind, ...)

Subjects
Nortriptyline -- Rankings, Medical research, Medicine, Experimental, Nervous system diseases -- Prevention, Migraine -- Prevention, Antilipemic agents -- Rankings, Health
Abstract

2022 FEB 18 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Nervous System Diseases and Conditions - Headache have been [...]

Published
2022

42. Olympic medalist promotes Lilly migraine medicine (with an asterisk): Swimmer doesn't use injectable he is paid to advertise

Author

Russell, John

Subjects
Eli Lilly and Co. -- Advertising, Migraine -- Prevention, Swimmers -- Beliefs, opinions and attitudes, Pharmaceutical industry -- Advertising, Business, Business, regional, Emgality (Medication) -- Advertising
Abstract

Did Olympic gymnast Mary Lou Retton really start her day with a bowl of Wheaties? Does superstar golfer Jordan Spieth really crack open a Coca-Cola after 18 holes? Product promotions [...]

Published
2021

43. Migraine and Headache Awareness Month: gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Treats & Prevents Migraine and Cluster Headaches

Subjects
Medical care, Cost of -- Health aspects, Migraine -- Prevention, Health care industry -- Health aspects, Health care industry, General interest, News, opinion and commentary
Abstract

ROCKAWAY, N.J.: electroCore, Inc. has issued the following news release: June is Migraine and Headache Awareness Month (MHAM) and according to The Migraine Research Foundation migraine disease affects 39 million [...]

Published
2021

44. Biohaven Showcases CGRP-Antagonist Franchise Data including Nurtec(r) ODT (rimegepant), Now Approved to Treat and Prevent Migraine Attacks, and Zavegepant with 19 Presentations at the 2021 Virtual Annual Scientific Meeting of the American Headache Society

Subjects
Societies, Migraine -- Prevention, Associations, institutions, etc., General interest, News, opinion and commentary, Nurtec (Medication)
Abstract

NEW HAVEN: Biohaven Pharmaceutical Holding Company Ltd. has issued the following press release: Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 19 abstracts, including one late-breaking presentation and [...]

Published
2021

45. CEFALY Technology Unveils Next-Generation Migraine Relief & Prevention Device: CEFALY DUAL Enhanced

Subjects
Medical equipment -- Product enhancement, Migraine -- Prevention, Physiological apparatus -- Product enhancement, Product enhancement, General interest, News, opinion and commentary
Abstract

NEW YORK: CEFALY Technology has issued the following news release: CEFALY Technology today announced the release of the new CEFALY DUAL Enhanced, the next-generation model of the dual-purpose, external Trigeminal [...]

Published
2021

46. The Ins & Outs of nVNS: Non-Invasive Vagus Nerve Stimulation Device Prevents and Relieves Pain From Migraines, Cluster Headaches & Other Conditions

Subjects
Medical research, Medicine, Experimental, Migraine -- Prevention, Pain -- Care and treatment, General interest, News, opinion and commentary
Abstract

ROCKAWAY: ELECTROCORE, INC. has issued the following news release: electroCore, a commercial stage bioelectronic medicine company, has developed a non-drug and non-invasive alternative to pharmaceuticals that safely and effectively stimulates [...]

Published
2021

47. CEFALY Technology Unveils Next-Generation Migraine Relief & Prevention Device: CEFALY DUAL Enhanced

Subjects
Medical equipment -- Product enhancement, Migraine -- Prevention, Physiological apparatus -- Product enhancement, Product enhancement, Business, News, opinion and commentary
Abstract

Now available, the sleek, reimagined external Trigeminal Nerve Stimulator offers multiple enhancements to make treating migraines easier and more effective NEW YORK, May 25, 2021 /PRNewswire/ -- CEFALY Technology today [...]

Published
2021

49. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age

Author

Lewis, Donald, Winner, Paul, Saper, Joel, Ness, Seth, Polverejan, Elena, Wang, Steven, Kurland, Caryn L., Nye, Jeff, Yuen, Eric, Eerdekens, Marielle, and Ford, Lisa

Subjects
Topiramate -- Usage, Topiramate -- Health aspects, Migraine -- Prevention, Migraine -- Demographic aspects, Experimental design -- Usage, Drug therapy -- Research
Published
2009

50. Chronic migraine sufferers given fresh hope thanks to 'life-changing' drug; The drug, called fremanezumab, has been shown to prevent chronic migraines in adults where at least three previous treatments have failed

Subjects
Adults, Migraine -- Prevention, Fremanezumab, Technology, Health, General interest, News, opinion and commentary
Abstract

Byline: By, Shivali Best It's a condition that's thought to affect 190,000 Brits every day, but chronic migraines could soon be treated with a 'life-changing' drug. The drug, called fremanezumab, [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results